View/Download PDF
CROSSMARK LOGO Buy Reprints
PDF

Translate this page into:

Commentary
23 (
4
); 361-362
doi:
10.4103/IJPC.IJPC_124_17

Commentary

Department of Palliative Care and Psychooncology, Tata Medical Center, Kolkata, West Bengal, India
Address for correspondence: Dr. Shrikant Atreya, Tata Medical Center, Major Arterial Road, Newtown, Rajarhat, Kolkata - 700 156, India. E-mail: naveensalins@gmail.com
Read COMMENTARY-ARTICLE associated with this article -
Licence

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher; therefore Scientific Scholar has no control over the quality or content of this article.

Cancer-related fatigue (CRF) is one of the most common problems facing patients both during and after completion of treatment. Overall 50%–90% of cancer patients experience fatigue the latter number corresponding with those undergoing active anticancer chemotherapy or radiotherapy and around 30% of patients continue to have moderate to severe fatigue 6 months after completion of treatment.[12] According to the National Comprehensive Cancer Network (NCCN) CRF is defined as “a distressing persistent, subjective sense of physical, emotional and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning.”[3] The pathophysiology of CRF has not been adequately elucidated, and multiple mechanisms have been proposed in its causation. Some of the factors include activation of proinflammatory cytokines (tumor necrosis factor alpha, interleukin 1, interleukin 6), dysregulation of serotoninergic system, hypothalamic pituitary–adrenal axis or circadian rythm, defective adenosine triphosphate (ATP) regeneration, cancer cachexia-anorexia syndrome, anemia, depression, insomnia, chemotherapy and radiotherapy and concurrent comorbidities such as hypothyroidism, infections, and organ failures. Multiple mechanisms have been proposed, and therapeutics are being investigated implying a multimodal approach for the management of fatigue.[4]

The authors in the present study[5] have highlighted a very important aspect of cancer care that is often under-recognized, under-reported, and under-treated resulting in a debilitating quality of life. The major challenge in the management of fatigue is identifying fatigue as a significant problem and nonavailability of objective assessment tool. Although the effort is being directed at developing an objective tool for measuring the physical and cognitive changes caused by fatigue, there is no validated tool for diagnosing fatigue and oftentimes objective assessment is clouded by behavioral manifestations as may be reported by family.[6] Visual analog scale (VAS) for the assessment of severity of fatigue may be used as an initial tool followed by detailed clinical examination and investigations commensurate with the clinical suspicion. The management of fatigue often necessitates a multimodal approach. For mild fatigue on a VAS of 1–3 nonpharmacological techniques such as exercise, yoga, cognitive-behavioral therapy, and sleep therapy can be used.[7] However, patients with moderate-to-severe fatigue with a VAS score of ≥4 may benefit from pharmacological intervention although the evidence to support the benefit of pharmacological intervention is low.

Many studies have proven the beneficial effects of exercise in patients with fatigue with a demonstrable improvement in quality of life. The current NCCN guidelines recommendation is to begin with low intensity and short duration exercise with modification of exercise plan depending on patient's response and severity of fatigue. An exercise plan that includes 20–30 min duration, three to five times a week may have a beneficial effect on patient's fatigue.[3] However, cancer patients who exercised more than 60 min reported an increase in fatigue. Interesting piece of work by Dimeo et al. reported endurance training-related decreases in both heart rate and blood lactate concentrations at submaximum intensities reflecting improved functional status and increased metabolic efficiency for a given workload. Endurance training induces improved metabolic efficiency. This could be explained by the fact that there is increased recruitment of the oxidative fibers and decrease in the glycolytic fibers. The oxidative fibers produce less lactate, metabolize the lactate, and oxidize them for fuel generation. Furthermore, oxidative fibers are more resilient to stress as compared to glycolytic fibers. Endurance training improves oxygen uptake by the exercising muscles, improve the cardiorespiratory function, blood oxygen transport, and muscle aerobic capacities (mitochondrial density or capillarization of muscle fibers). Exercise can attenuate cardiac and skeletal toxicities of certain chemotherapies such as anthracyclines and myeloablative therapies. It triggers erythropoeisis and attenuates skeletal atrophy by suppressing the inflammatory response, enhancing the rate of protein synthesis, and antioxidant enzyme activities.[8] Exercise training has proven manifold benefits in the management of fatigue, thus, early institution of fatigue management program right from the point of initiating the disease directed treatment may help in obtaining better outcomes with respect to patient quality of life and physical functioning. This will also prevent premature discontinuation of the disease directed treatment, keep a check on patient adherence, and prevent drop outs from treatment.

REFERENCES

  1. , , , , , . Cancer-related fatigue: Evolving concepts in evaluation and treatment. Cancer. 2003;98:1786-801.
    [Google Scholar]
  2. , , . How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast Cancer Res Treat. 2008;112:5-13.
    [Google Scholar]
  3. , , , , , , . Cancer-related Fatigue, Version 2.2015. J Natl Compr Canc Netw. 2015;13:1012-39.
    [Google Scholar]
  4. , . Pathophysiology of cancer-related fatigue. Clin J Oncol Nurs. 2008;12(5 Suppl):11-20.
    [Google Scholar]
  5. , , . Effect of Aerobic Exercise on Cancer-related Fatigue. Indian J Palliat Care. 2017;23:355-61.
    [Google Scholar]
  6. , . The measurement, causes and effective management of cancer-related fatigue. Int J Palliat Nurs. 2002;8:120-8.
    [Google Scholar]
  7. , , , , . Cancer-related fatigue: A review. Rev Assoc Med Bras. 2011;57:211-9.
    [Google Scholar]
  8. , , , . Cancer-related fatigue: Can exercise physiology assist oncologists? Lancet Oncol. 2003;4:616-25.
    [Google Scholar]

    Fulltext Views
    59

    PDF downloads
    0
    View/Download PDF
    Download Citations
    BibTeX
    RIS
    Show Sections